Recursion Prices 61.54M-Share Offering at $3.25; Underwriters Led by Leerink, Goldman
Recursion Pharmaceuticals (RXRX) plans to raise $200M by selling 61.54M shares at $3.25 each, with proceeds funding operations and R&D. The offering, led by Leerink and Goldman, is set to close Oct 16, 2026, per an SEC filing.
How this was made
The 30-second read
Why it matters
The $200 M raise provides runway for R&D but introduces dilution risk, likely pressuring the stock in the near term.
Market read
Primary disclosure of a large equity raise for a mid‑cap biotech; immediate trading relevance.
What to watch
Potential strategic partnership with underwriters or hidden covenants in the offering.
Background
Recursion Pharmaceuticals is a clinical‑stage biotech focused on AI‑driven drug discovery.
Ticker impact
Recursion Pharmaceuticals filed an 8‑K announcing a 61.5M‑share public offering at $3.25, raising about $200 M.
likely downward pressure as the market prices in dilution
A $200 M primary offering is material for a mid‑cap biotech; investors typically react with sell‑offs on dilution news.
Market effects
May increase supply of biotech equity, prompting peers to reassess financing options.
Limited to US biotech investors; no broader regional effect.
Minor global impact; primarily relevant to US‑listed biotech sector.
Counterpoint
If the capital raise funds a breakthrough pipeline, the long‑term upside could outweigh short‑term dilution.
Key entities
- UnderwriterLeerink Partners
Lead underwriter for the offering.
- UnderwriterGoldman Sachs
Co‑underwriter for the offering.
